Yahoo Canada Web Search

Search results

1. www.fiercebiotech.com › medtech › abbott-subsidiaryAbbott subsidiary Alere pays $160M to settle false Medicare ...

   www.fiercebiotech.com › medtech › abbott-subsidiary

   • Cached

   Aug 3, 2021 · The deal did eventually go through—after Alere filed a countercomplaint to reject Abbott’s offer of terminating the proceedings for $50 million—at a price about $500 million below the ...

2. www.businessinsurance.com › article › 20210802Abbott Labs to pay $160M over kickbacks, false diabetes claims

   www.businessinsurance.com › article › 20210802

   • Cached

   Aug 2, 2021 · August 02, 2021 Reprints. Regulation. (Reuters) — Abbott Laboratories will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to ...

3. www.reuters.com › business › healthcareAbbott Labs to pay $160 mln over kickbacks, false diabetes ...

   www.reuters.com › business › healthcare

   Aug 2, 2021 · Abbott Laboratories (ABT.N) will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to diabetes patients, including "free" or "no ...

4. www.massdevice.com › abbott-owned-alere-has-to-payAbbott has to pay $160M in another Alere-related case

   www.massdevice.com › abbott-owned-alere-has-to-pay

   • Cached

   Aug 4, 2021 · August 4, 2021 By Sean Whooley. Abbott (NYSE:ABT) has agreed to pay $160 million to resolve False Claims Act violation allegations it inherited from Alere, which it acquired in 2017. The ...

5. seekingalpha.com › news › 3723310-abbott-to-pay-160mAbbott to pay $160M to Feds to resolve Medicare diabetes ...

   seekingalpha.com › news › 3723310-abbott-to-pay-160m

   Aug 2, 2021 · Abbott Laboratories (ABT +0.0%) has agreed to pay $160M to resolve allegations it violated the False Claims Act in relation to mail-order diabetic testing supplies and Medicare, according to the ...

   • Author: Jonathan Block

6. dam.abbott.com › en-us › hubFourth-Quarter And Full-Year 2021 Results - Abbott Laboratories

   dam.abbott.com › en-us › hub

   2021 results worldwide sales growth on an organic basis* $11.5b +7.7% 1 $43.1b +22.9% 2 $5.21 3 43% 4 full-year 2021: key business units5 growth on an organic basis* +7.7% +10.4% +42.7% diagnostics +19.4% medical devices established pharmaceuticals nutrition q4 q4 full year full year reflects nearly adjusted diluted eps growth versus prior year ...

7. People also ask

   How did Abbott sales perform in Q4 2021?

   • On a GAAP basis, fourth-quarter Abbott sales increased 7.2%. 2. On a GAAP basis, full-year 2021 Abbott sales increased 24.5%. 3. Full-year 2021 GAAP diluted EPS from continuing operations was $3.94. 4. Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58% growth. 5.

   Fourth-Quarter And Full-Year 2021 Results - Abbott Laboratories

   dam.abbott.com/en-us/hub/ABT-4Q21-Earnings-Infographic-FINAL.pdf

   See all results for this question

   Will Abbott Laboratories pay $160 million for a 'no cost' glucose monitor?

   • REUTERS/Adnan Abidi Acquire Licensing Rights Aug 2 (Reuters) - Abbott Laboratories (ABT.N) will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to diabetes patients, including "free" or "no cost" glucose monitors, the U.S. Department of Justice said.

   Abbott Labs to pay $160 mln over kickbacks, false diabetes ... - Reuters

   www.reuters.com/business/healthcare-pharmaceuticals/us-says-abbott-units-pay-160-mln-resolve-alleged-false-medicare-claims-2021-08-02/

   See all results for this question

   How much diluted earnings does Abbott expect in 2022?

   • Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43. Abbott forecasts specified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

   Fourth-Quarter And Full-Year 2021 Results - Abbott Laboratories

   dam.abbott.com/en-us/hub/ABT-4Q21-Earnings-Infographic-FINAL.pdf

   See all results for this question

   How did Abbott perform in January 2022?

   • Abbott significantly exceeded guidance issued in January 2022, continues strengthening product portfolio. Combine Abbott's diverse business portfolio with a steady drumbeat of new product approvals and what do you get? A solid full-year financial performance and momentum going forward.

   Abbott Q4 Earnings: Continued Resiliency | Abbott Newsroom

   www.abbott.com/corpnewsroom/strategy-and-strength/Abbott-Q4-earnings-continued-resiliency.html

   See all results for this question

   What were Abbott's Q4 results?

   • For the quarter: For the full year: Abbott issued full-year guidance for 2023 adjusted diluted EPS from continuing operations of $4.30 to $4.50. 3 These are the key fourth-quarter highlights: Sales of FreeStyle Libre systems exceeded $1 billion with U.S. sales growing more than 40%.

   Abbott Q4 Earnings: Continued Resiliency | Abbott Newsroom

   www.abbott.com/corpnewsroom/strategy-and-strength/Abbott-Q4-earnings-continued-resiliency.html

   See all results for this question

   How much diluted EPS does Abbott expect in 2022?

   • 1 Fourth-quarter 2022 GAAP diluted EPS of $0.59. 2 Full-year 2022 GAAP diluted EPS of $3.91. 3 Abbott projects 2023 diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25. 4 Smallest size determined by volume in cubic centimeters. 5 Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151); 2022. Forward-Looking Statements

   Abbott Q4 Earnings: Continued Resiliency | Abbott Newsroom

   www.abbott.com/corpnewsroom/strategy-and-strength/Abbott-Q4-earnings-continued-resiliency.html

   See all results for this question

8. www.abbott.com › corpnewsroom › strategy-andAbbott Q4 Earnings: Continued Resiliency | Abbott Newsroom

   www.abbott.com › corpnewsroom › strategy-and

   • Cached

   Jan 25, 2023 · For the quarter: For the full year: Abbott issued full-year guidance for 2023 adjusted diluted EPS from continuing operations of $4.30 to $4.50. 3. These are the key fourth-quarter highlights: Sales of FreeStyle Libre systems exceeded $1 billion with U.S. sales growing more than 40%.